Endocrine System Channel
Related Channels

Precautions and Warnings With Extended-Release Exenatide

If you are going to use extended-release exenatide, your healthcare provider must first be aware of any allergies or other medical issues you may have. In particular, if you or your family has a history of a certain type of thyroid cancer, you should not use extended-release exenatide. Safety precautions also include warnings of potential drug interactions and an increased risk for pancreatitis.

What Should I Tell My Healthcare Provider?

You should talk with your healthcare provider prior to using extended-release exenatide (Bydureon™) if you have:
Also, let your healthcare provider know if you are:
  • Pregnant or thinking of becoming pregnant
  • Breastfeeding.
You should also tell your healthcare provider about all other medications you are taking, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Specific Extended-Release Exenatide Precautions and Warnings

Some warnings and precautions to be aware of prior to using this drug include the following:
  • Very preliminary data suggests incretin mimetics, such as extended-release exenatide, may increase the risk of precancerous cellular changes (called pancreatic duct metaplasia) in people with type 2 diabetes. Researchers are continuing to study the possibility that incretin mimetics might increase the risk of pancreatic cancer, although at this time there is not enough information to know for sure if there is any increased risk.
  • Even though it is taken by injection, extended-release exenatide is not insulin and should not be used to treat type 1 diabetes or diabetic ketoacidosis.
  • In laboratory rats, extended-release exenatide was shown to cause thyroid tumors, which were cancerous in some cases. However, it is unknown if the drug causes such tumors in humans. Be sure to let your healthcare provider know right away if you develop any signs or symptoms of a thyroid tumor, such as:
    • A lump in the neck
    • Difficulty swallowing
    • Shortness of breath
    • A persistent hoarse voice
    • Increased calcitonin blood levels (found using a blood test).
  • Extended-release exenatide may increase the risk of pancreatitis. You may be at a higher risk for this condition if you have ever had pancreatitis in the past. Let your healthcare provider know immediately if you develop any signs or symptoms of pancreatitis, such as:
    • Vomiting
    • Severe, persistent abdominal (stomach) pain, sometimes radiating to the back.
  • When used by itself, extended-release exenatide is not particularly likely to cause dangerously low blood sugar levels (hypoglycemia). However, combining it with insulin, or oral medications that increase insulin production, appears to increase this risk (see Drug Interactions With Extended-Release Exenatide for further information).
  • Extended-release exenatide is not recommended for use in people with severe kidney disease.
  • There have been a few reports of decreased kidney function, including kidney failure, in people using extended-release exenatide. However, it is not clear if these cases were caused by or related to this medication.
  • Extended-release exenatide has not been thoroughly studied in people with severe gastrointestinal problems, including diabetic gastroparesis. If you have a gastrointestinal problem, your healthcare provider will probably need to monitor you more closely, as extended-release exenatide slows down the movement of food through the digestive tract. In general, this medication is not recommended for people with severe gastrointestinal problems.
  • Extended-release exenatide is a manufactured (synthetic) version of a protein found in the saliva of Gila monster lizards. As such, it may cause allergic reactions. Talk to your healthcare provider if you develop an allergic reaction after using this medication. Also, in some people, the immune system may attack extended-release exenatide, perhaps making it less effective.
  • It is unknown whether extended-release exenatide passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to using the drug (see Bydureon and Breastfeeding).
  • Extended-release exenatide is a pregnancy Category C medication. This means that it may not be safe for use during pregnancy, although the full risks are currently unknown (see Bydureon and Pregnancy).
Steps to Prevent or Delay Diabetic Nerve Damage

Extended-Release Exenatide Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.